Last reviewed 2026-04-23 · How we verify

ACI-19764 at dose A1

AC Immune SA · Phase 1 active Small molecule

ACI-19764 at dose A1 is a Small molecule drug developed by AC Immune SA. It is currently in Phase 1 development.

At a glance

Generic name	ACI-19764 at dose A1
Sponsor	AC Immune SA
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACI-19764 at dose A1 CI brief — competitive landscape report
ACI-19764 at dose A1 updates RSS · CI watch RSS
AC Immune SA portfolio CI

Frequently asked questions about ACI-19764 at dose A1

What is ACI-19764 at dose A1?

ACI-19764 at dose A1 is a Small molecule drug developed by AC Immune SA.

Who makes ACI-19764 at dose A1?

ACI-19764 at dose A1 is developed by AC Immune SA (see full AC Immune SA pipeline at /company/ac-immune-sa).

What development phase is ACI-19764 at dose A1 in?

ACI-19764 at dose A1 is in Phase 1.

Manufacturer: AC Immune SA — full pipeline
Compare: ACI-19764 at dose A1 vs similar drugs
Pricing: ACI-19764 at dose A1 cost, discount & access